CN114984045A - Lavage liquid preparation for surgical operation - Google Patents
Lavage liquid preparation for surgical operation Download PDFInfo
- Publication number
- CN114984045A CN114984045A CN202210769518.6A CN202210769518A CN114984045A CN 114984045 A CN114984045 A CN 114984045A CN 202210769518 A CN202210769518 A CN 202210769518A CN 114984045 A CN114984045 A CN 114984045A
- Authority
- CN
- China
- Prior art keywords
- lavage fluid
- chitosan
- phosphate buffer
- nonoxynol
- balance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000007788 liquid Substances 0.000 title description 2
- 229920001661 Chitosan Polymers 0.000 claims abstract description 24
- 239000012530 fluid Substances 0.000 claims abstract description 22
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920000153 Povidone-iodine Polymers 0.000 claims abstract description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 12
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 12
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 12
- 229960001621 povidone-iodine Drugs 0.000 claims abstract description 12
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 12
- 229920000847 nonoxynol Polymers 0.000 claims abstract description 11
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 210000003127 knee Anatomy 0.000 claims description 3
- 238000011146 sterile filtration Methods 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229940094512 nonoxynol-12 Drugs 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 208000031737 Tissue Adhesions Diseases 0.000 abstract description 4
- 206010052428 Wound Diseases 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000003187 abdominal effect Effects 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 3
- 230000002289 effect on microbe Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a lavage fluid preparation for surgical operation, which comprises the following components in percentage by mass: 9-12% of sodium hyaluronate, 25-38% of sodium dihydrogen phosphate, 8-15% of nonoxynol, 5-8% of chitosan, 3-6% of povidone iodine, 0.5-2% of water-soluble chitosan and the balance of phosphate buffer solution. Through reasonable proportion and combination of the components, the form of tissue adhesion can be effectively prevented, the healing of wounds can be promoted, the bleeding can be effectively stopped, the sterilization effect can be achieved, and the inhibition effect on microorganisms is excellent; in addition, the lavage fluid can be prepared into different concentration ratios according to different operation requirements, has wide application and meets various clinical requirements. Is widely applicable to operations such as ophthalmology, surgical operation, abdominal chemotherapy and the like, and has wide application prospect.
Description
Technical Field
The invention relates to a preparation, in particular to a surgical lavage fluid preparation.
Background
Adhesions are abnormal structures formed by the connective tissue fibrous band joining adjacent tissues or organs, and postoperative tissue adhesion is one of the most serious postoperative complications resulting from the surgical procedure. Currently, during clinical treatment, hydrophilic solutions are used to coat tissues that are dry to touch and surgically traumatized into the peritoneum, and to contact the tissues before or during surgery to prevent adhesions. However, the existing hydrophilic solution has single function, only can play a role in preventing adhesion, but cannot play a role in effectively stopping bleeding and inhibiting bacteria.
Therefore, there is an urgent need to develop a lavage fluid preparation for surgery that can not only prevent adhesion, but also stop bleeding and inhibit bacteria.
Disclosure of Invention
To overcome the above-mentioned drawbacks, the present invention provides a surgical lavage fluid preparation.
The technical scheme adopted by the invention for solving the technical problems is as follows: a surgical lavage fluid preparation comprises the following components in percentage by mass:
9-12% of sodium hyaluronate, 25-38% of sodium dihydrogen phosphate, 8-15% of nonoxynol, 5-8% of chitosan, 3-6% of povidone iodine, 0.5-2% of water-soluble chitosan and the balance of phosphate buffer solution.
In a preferred embodiment of the invention, the sodium hyaluronate is 10-12%, the sodium dihydrogen phosphate is 30-38%, the nonoxynol is 10-15%, the chitosan is 6-8%, the povidone iodine is 4-6%, the water-soluble chitosan is 1-2%, and the balance is phosphate buffer.
In a preferred embodiment of the invention, 112% of sodium hyaluronate, 32% of sodium dihydrogen phosphate, 12% of nonoxynol, 7% of chitosan, 4% of povidone iodine, 1% of water-soluble chitosan and the balance of phosphate buffer.
In a preferred embodiment of the invention, the lavage fluid preparation is filled after the filtration sterilization by the filtration device.
In a preferred embodiment of the present invention, the phosphate buffer is a disodium hydrogen phosphate solution.
In a preferred embodiment of the invention, the phosphate buffer solution is used for sterile filtration treatment of the absorbent knee pad, and the phosphate buffer solution is required to be completely dissolved.
The invention has the beneficial effects that: through reasonable proportion and combination of the components, the form of tissue adhesion can be effectively prevented, the healing of wounds can be promoted, the bleeding can be effectively stopped, the sterilization effect can be achieved, and the inhibition effect on microorganisms is excellent; in addition, the lavage fluid can be prepared into different concentration ratios according to different operation requirements, has wide application and meets various clinical requirements. Is widely applicable to operations such as ophthalmology, surgical operation, abdominal chemotherapy and the like, and has wide application prospect.
Detailed Description
In the description of the present invention, it is to be understood that the terms "center," "longitudinal," "lateral," "length," "width," "thickness," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," "clockwise," "counterclockwise," and the like are used merely for convenience in describing and simplifying the description, and do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus, are not to be considered as limiting. Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, features defined as "first", "second", may explicitly or implicitly include one or more of the described features. In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
The invention relates to a surgical lavage fluid preparation which comprises the following components in percentage by mass:
9-12% of sodium hyaluronate, 25-38% of sodium dihydrogen phosphate, 8-15% of nonoxynol, 5-8% of chitosan, 3-6% of povidone iodine, 0.5-2% of water-soluble chitosan and the balance of phosphate buffer.
As a preferable mode, the lavage fluid preparation for surgical operation of the invention comprises the following components by mass percent: 10-12% of sodium hyaluronate, 30-38% of sodium dihydrogen phosphate, 10-15% of nonoxynol, 6-8% of chitosan, 4-6% of povidone iodine, 1-2% of water-soluble chitosan and the balance of phosphate buffer.
1, implementation: a surgical lavage fluid preparation comprises the following components in percentage by mass: 112% of sodium hyaluronate, 32% of sodium dihydrogen phosphate, 12% of nonoxynol, 7% of chitosan, 4% of povidone iodine, 1% of water-soluble chitosan and the balance of phosphate buffer. The lavage fluid preparation in this application is filled after filter equipment filtration sterilization. The phosphate buffer in this application is a disodium hydrogen phosphate solution. The phosphate buffer solution imbibition knee pad sterile filtration treatment in the application needs to be completely dissolved.
Example 2: the lavage fluid preparation for surgical operation of the invention comprises the following components by mass percent: 11% of sodium hyaluronate, 35% of sodium dihydrogen phosphate, 15% of nonoxynol, 7% of chitosan, 5% of povidone iodine, 2% of water-soluble chitosan and the balance of phosphate buffer solution.
Example 3:
the surgical lavage fluid preparation of the invention comprises the following components by mass percent: 12% of sodium hyaluronate, 38% of sodium dihydrogen phosphate, 12% of nonoxynol, 7% of chitosan, 4% of povidone iodine, 1.5% of water-soluble chitosan and the balance of phosphate buffer.
The invention can effectively prevent the form of tissue adhesion, promote the healing of wounds and effectively stop bleeding by reasonable proportion and combination of all components, can play a role in sterilization and has excellent inhibition effect on microorganisms; in addition, the lavage fluid can be prepared into different concentration ratios according to different operation requirements, has wide application and meets various clinical requirements. Is widely applicable to operations such as ophthalmology, surgical operation, abdominal chemotherapy and the like, and has wide application prospect.
In the description herein, references to the description of the terms "one embodiment," "certain embodiments," "an illustrative embodiment," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
In summary, although the present invention has been described with reference to the preferred embodiments, the above-described preferred embodiments are not intended to limit the present invention, and those skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention, therefore, the scope of the present invention shall be determined by the appended claims.
Claims (6)
1. A surgical lavage fluid preparation is characterized by comprising the following components in percentage by mass:
9-12% of sodium hyaluronate, 25-38% of sodium dihydrogen phosphate, 8-15% of nonoxynol, 5-8% of chitosan, 3-6% of povidone iodine, 0.5-2% of water-soluble chitosan and the balance of phosphate buffer solution.
2. A surgical lavage fluid preparation as claimed in claim 1 wherein sodium hyaluronate 10-12%, sodium dihydrogen phosphate 30-38%, nonoxynol 10-15%, chitosan 6-8%, povidone iodine 4-6%, water soluble chitosan 1-2%, and the balance phosphate buffer.
3. A surgical lavage fluid formulation as claimed in claim 2 wherein sodium hyaluronate 112%, sodium dihydrogen phosphate 32%, nonoxynol 12%, chitosan 7%, povidone-iodine 4%, water soluble chitosan 1%, the balance being phosphate buffer.
4. A surgical lavage fluid preparation according to claim 1 in which the lavage fluid preparation is filled after filter sterilisation by a filter means.
5. A surgical lavage fluid formulation according to claim 1, wherein the phosphate buffer is disodium hydrogen phosphate solution.
6. A surgical lavage fluid formulation according to claim 1 wherein the phosphate buffer solution is applied by sterile filtration from the absorbent knee pad, the phosphate buffer solution being required to be completely dissolved.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210769518.6A CN114984045A (en) | 2022-07-01 | 2022-07-01 | Lavage liquid preparation for surgical operation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210769518.6A CN114984045A (en) | 2022-07-01 | 2022-07-01 | Lavage liquid preparation for surgical operation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114984045A true CN114984045A (en) | 2022-09-02 |
Family
ID=83019327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210769518.6A Pending CN114984045A (en) | 2022-07-01 | 2022-07-01 | Lavage liquid preparation for surgical operation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114984045A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028280A (en) * | 2006-03-01 | 2007-09-05 | 上海其胜生物制剂有限公司 | Lavage liquor preparation for operation and its production |
| US9155709B1 (en) * | 2014-11-13 | 2015-10-13 | Hugh A. House, Sr. | Buffered hydroalcoholic povidone iodine composition and method |
| CN107823216A (en) * | 2017-11-16 | 2018-03-23 | 李雪红 | A kind of new lavage liquor preparation |
| CN107854488A (en) * | 2017-11-16 | 2018-03-30 | 李雪红 | A kind of surgical operation lavage liquor preparation |
-
2022
- 2022-07-01 CN CN202210769518.6A patent/CN114984045A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028280A (en) * | 2006-03-01 | 2007-09-05 | 上海其胜生物制剂有限公司 | Lavage liquor preparation for operation and its production |
| US9155709B1 (en) * | 2014-11-13 | 2015-10-13 | Hugh A. House, Sr. | Buffered hydroalcoholic povidone iodine composition and method |
| CN107823216A (en) * | 2017-11-16 | 2018-03-23 | 李雪红 | A kind of new lavage liquor preparation |
| CN107854488A (en) * | 2017-11-16 | 2018-03-30 | 李雪红 | A kind of surgical operation lavage liquor preparation |
Non-Patent Citations (1)
| Title |
|---|
| 郭迅;裴明祥;邱福轩;田银海;: "医用几丁糖与透明质酸钠预防腹部术后肠粘连的对比研究" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240066179A1 (en) | Wound dressing comprising hyaluronic acid-calcium and polylysine and manufacturing method therefor | |
| JP5489999B2 (en) | Surgical hydrogel | |
| CA2743920C (en) | Composition for preventing adhesion | |
| US7265098B2 (en) | Polyacid/polyalkylene oxide gels and methods for their delivery | |
| KR101125934B1 (en) | Temperature Sensitive Tissue Adhesion Prevention Composition And Method For Preparing Thereof | |
| KR101330652B1 (en) | Anti―adhesion polymer composition able to load growth factors | |
| KR20030031480A (en) | Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use | |
| US9192574B2 (en) | Chitosan paste wound dressing | |
| CA2316248A1 (en) | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions | |
| CN1839875A (en) | Surgical flush fluid and its preparing process and application | |
| US20150119357A1 (en) | Chitosan stenting paste | |
| BR112020016382A2 (en) | HEMOSTATIC COMPOSITION, METHOD OF MANUFACTURING THE SAME, AND, METHOD OF HEMOSTASIA | |
| KR20190084840A (en) | temperature sensitive polymer composition | |
| US20230220190A1 (en) | Anti-adhesion polymer composition | |
| CN114984045A (en) | Lavage liquid preparation for surgical operation | |
| CN101028280B (en) | Lavage liquor preparation for operation and its production | |
| CN107823216A (en) | A kind of new lavage liquor preparation | |
| US6090997A (en) | Method and composition for preventing surgical adhesions and tissue damage employing fluorinated polymers | |
| PL194109B1 (en) | Dextrin-containing composition for preventing surgical adhesions | |
| RU2744538C1 (en) | Method for the prevention of intestinal suture failure in conditions of widespread peritonitis in the experiment | |
| KR20100013658A (en) | Multi-layer tissue adhesion barrier membrane | |
| CN107737137A (en) | A kind of lavage liquor preparation | |
| KR20010107068A (en) | A conglutination inhibitor | |
| CN112043879A (en) | Carboxymethyl chitosan surgical anti-adhesion gel and preparation method thereof | |
| CN107661346A (en) | A kind of novel operation lavage liquor preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220902 |
|
| WD01 | Invention patent application deemed withdrawn after publication |